EPO‐GER‐20.

Methods	randomized controlled trial, not placebo‐controlled
Participants	n = 93, small cell lung cancer (extensive stage); concomitant treatment: chemotherapy
Interventions	drug = Epoetin alpha dose = 10000 IU sc TIW hb‐target = 12‐14 g/dL planned ESA duration = during chemotherapy
Outcomes	Primary: rate of patients with anemia; secondary: QoL, tolerability of ESA, transfusion, effectiveness of chemotherapy
Notes	study number = 31678
Risk of bias
Bias	Authors' judgement	Support for judgement
Adequate sequence generation?	Unclear risk	Patients were assigned with a randomization code provided by Janssen‐Cilag
Allocation concealment?	Unclear risk	assigned envelopes, sequentially numbered, but it is unclear whether they were sealed and opaque